Peng Junjie, Yang Fang, Chen Jianlin, Guo Shaohua, Zhang Linhan, Deng Dinghao, Li Jiangling, Lv Xuebin, Gao Rong
College of Life Science, Sichuan University, Chengdu 610065, China.
New Drug Pre-Production Key Laboratory of Sichuan Province, Chengdu 610093, China.
Biology (Basel). 2022 Nov 30;11(12):1747. doi: 10.3390/biology11121747.
Drug resistance in economic animals to pathogens is a matter of widespread concern due to abuse of antibiotics. In order to develop a safe and economical immunopotentiator to raise the immunity and antibacterial response as a replacement for antibiotics, a recombinant yeast co-expressing pig interleukin-17 (IL-17) and IL-22 was constructed and designated as Po1h-pINA1297-IL-17/22. To evaluate the immunoregulator activities of Po1h-pINA1297-IL-17/22, two experiment groups (oral inoculation with Po1h-pINA1297 or Po1h-pINA1297-IL-17/22) and a negative control group (PBS) were set up using 4-week-old female BALB/c mice (10/group). The level of cytokines, including IL-2, IL-4, IL-10, and IFN-γ, were detected by ELISA, and the circulating CD4+ and CD8+ lymphocytes were quantified by flow cytometry. The IgG and secretory IgA (SIgA) levels in both small intestine and fecal matter were also measured by ELISA. The results indicated that the IgG antibody titer and SIgA concentration increased significantly in the Po1h-pINA1297-IL17/22 group in comparison with the controls (p < 0.05) and so did the cytokine levels in the serum (IL-2, IL-4, IL-10, and IFN-γ). In addition, CD4+ and CD8+ T cells were also obviously elevated in the Po1h-pINA1297-IL17/22 group on 35th day (p < 0.05). After challenge with pathogenic Salmonella typhimurium, the Po1h-pINA1297-IL17/22 group showed a relatively higher survival rate without obvious infectious symptoms. On the contrary, the mortality of control group reached 80% due to bacterial infection. As for the piglet experiment, 30 healthy 7-day piglets were similarly attributed into three groups. The oral inoculation of piglets with Po1h-pINA1297-IL17/22 also markedly improved the growth performance and systemic immunity (up-regulations of IL-4, IL-6, IL-15, IL-17, IL-22, and IL-23). Overall, the results indicated that Po1h-pINA1297-IL17/22 effectively promoted the humoral and cellular immunity against bacterial infection. These proved the promising potential of Po1h-pINA1297-IL-17/22 to be a potent immunopotentiator for the prevention of microbial pathogen infections.
由于抗生素的滥用,经济动物对病原体的耐药性成为一个广泛关注的问题。为了开发一种安全且经济的免疫增强剂来提高免疫力和抗菌反应以替代抗生素,构建了共表达猪白细胞介素-17(IL-17)和IL-22的重组酵母,并将其命名为Po1h-pINA1297-IL-17/22。为了评估Po1h-pINA1297-IL-17/22的免疫调节活性,使用4周龄雌性BALB/c小鼠(每组10只)设立了两个实验组(口服接种Po1h-pINA1297或Po1h-pINA1297-IL-17/22)和一个阴性对照组(PBS)。通过ELISA检测包括IL-2、IL-4、IL-10和IFN-γ在内的细胞因子水平,并通过流式细胞术对循环中的CD4+和CD8+淋巴细胞进行定量。还通过ELISA测量小肠和粪便中的IgG和分泌型IgA(SIgA)水平。结果表明,与对照组相比,Po1h-pINA1297-IL17/22组的IgG抗体效价和SIgA浓度显著增加(p<0.05),血清中的细胞因子水平(IL-2、IL-4、IL-10和IFN-γ)也是如此。此外,在第35天,Po1h-pINA1297-IL17/22组的CD4+和CD8+T细胞也明显升高(p<0.05)。在用致病性鼠伤寒沙门氏菌攻击后,Po1h-pINA1297-IL17/22组显示出相对较高的存活率,且无明显感染症状。相反,对照组由于细菌感染死亡率达到80%。至于仔猪实验,30只健康的7日龄仔猪同样分为三组。仔猪口服接种Po1h-pINA1297-IL17/22也显著改善了生长性能和全身免疫力(IL-4、IL-6、IL-15、IL-17、IL-22和IL-23上调)。总体而言,结果表明Po1h-pINA1297-IL17/22有效地促进了针对细菌感染的体液免疫和细胞免疫。这些证明了Po1h-pINA1297-IL-17/22作为预防微生物病原体感染的有效免疫增强剂具有广阔的潜力。